Vivos Therapeutics profit margin VVOS
Gross, operating and net profit as a share of revenue over the last twelve months, from 2020.
- Net margin, 12 months
- n/m
- not a meaningful number
- Peer median
- 8.6%
Vivos Therapeutics' net margin works out at −122% over the last twelve months, but it is not a meaningful number: a margin outside minus 100% to 100% is moved by items that are not sales.
Profit margin over time
GrossOperatingNet
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | n/a | n/a | 60.4% |
| FY2024 | −74.1% | −74.3% | 60.0% |
| FY2023 | −98.4% | n/a | 59.9% |
| FY2022 | n/a | n/a | 62.5% |
| FY2021 | n/a | n/a | 74.6% |
| FY2020 | −92.3% | −92.1% | 79.7% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | n/a | n/a | n/a | |
| Q1 FY26 | n/a | n/a | n/a | |
| Q4 FY25 | n/a | n/a | n/a | |
| Q3 FY25 | −98.8% | −12.6 pts | −94.3% | |
| Q2 FY25 | −99.5% | −13.6 pts | −98.9% | |
| Q1 FY25 | −76.8% | n/a | −77.3% | |
| Q4 FY24 | −74.1% | +24.3 pts | −74.3% | |
| Q3 FY24 | −86.2% | n/a | −85.7% | |
| Q2 FY24 | −85.9% | n/a | −96.2% | |
| Q1 FY24 | n/a | n/a | n/a | |
| Q4 FY23 | −98.4% | n/a | n/a | |
| Q3 FY23 | n/a | n/a | n/a |
Against its peers
Companies in Healthcare nearest Vivos Therapeutics' size, closest first, today.
| Company | Profit margin |
|---|---|
| VVOSVivos Therapeutics | n/m |
| OXBROXBRIDGE RE HOLDINGS | 4.7% |
| EDUCEducational Development | 8.6% |
| GTIMGood Times Restaurants | 1.7% |
| MDRRMedalist Diversified | 80.2% |
| BCGBinah Capital | 2.2% |
| VIPVulcan Infrastructure & Power | 1.0% |
| MXCMexco Energy | 23.3% |
| CKXCKX Lands | n/m |
| MSGMMotorsport Games | 16.2% |
| ATCHAtlasClear | 9.8% |
| Peer median | 8.6% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Vivos Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.